We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
genOway and Griffith University Sign Research Partnership and World-Wide Exclusive License for Olfactory Stem Cells Technology
News

genOway and Griffith University Sign Research Partnership and World-Wide Exclusive License for Olfactory Stem Cells Technology

genOway and Griffith University Sign Research Partnership and World-Wide Exclusive License for Olfactory Stem Cells Technology
News

genOway and Griffith University Sign Research Partnership and World-Wide Exclusive License for Olfactory Stem Cells Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "genOway and Griffith University Sign Research Partnership and World-Wide Exclusive License for Olfactory Stem Cells Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

genOway reports an agreement with the Griffith University (Brisbane, Australia) on a eight-months research partnership with its Eskitis Institute for Cell and Molecular Therapies focusing on autologous olfactory adult stem cells. This research program is coupled with a worldwide exclusive license to genOway for the rodent transgenic business.

This technology using adult stem cells of the olfactory bulb has been characterized on humans, mice and rats. Germline transmission has been demonstrated in mice, thus validating their use for the creation of animal models. The eight-month research program aims at establishing germline transmission in rats using existing rat olfactory adult stem cells. This technology would provide a unique tool for rat models and certain mice strains, which remained unreachable using embryonic stem cells.

According to the terms of the agreement, both partners will each bear the cost of their R&D efforts and genOway will have an exclusive license on the technologies for the creation and distribution of mouse and rat genetically modified models.

Mr. Nicholas Mathiou, Director of Griffith Enterprise, Griffith University’s technology commercialization office, said: “Adult stem cells will revolutionize diagnostics, drug development and therapy. This technology really constitutes a leap forward this goal. We believe that genOway through its world unique expertise and rich customers’ portfolio stands out as the best partner to develop and market this technology.”
Advertisement